Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report.

IF 2.8 Q2 Pharmacology, Toxicology and Pharmaceutics

Drugs in Context Pub Date : 2025-06-24 eCollection Date: 2025-01-01 DOI:10.7573/dic.2025-4-6

Alessia Lancianese, Elena Maccaroni, Laura Zepponi, Riccardo Giampieri, Rossana Berardi

{"title":"Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report.","authors":"Alessia Lancianese, Elena Maccaroni, Laura Zepponi, Riccardo Giampieri, Rossana Berardi","doi":"10.7573/dic.2025-4-6","DOIUrl":null,"url":null,"abstract":"Advanced endometrial carcinoma (EC) is typically associated with poor prognosis. However, recent advances have revolutionized therapeutic strategies. In patients with microsatellite stable (MSS) advanced EC, pembrolizumab plus lenvatinib have significantly improved overall survival, progression-free survival and response rate compared to standard chemotherapy. We describe the case of a 63-year-old woman with advanced endometrioid adenocarcinoma exhibiting mismatch repair proficiency (pMMR) and MSS who started treatment with pembrolizumab and lenvatinib after failing multiple lines of therapy. The patient had a favourable response, with mild side effects, and continues to receive treatment. Our experience supports pembrolizumab plus lenvatinib as a promising therapeutic option for patients with advanced recurrent EC with pMMR/MSS. This article is part of the New treatment options for advanced endometrial carcinoma Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221131/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2025-4-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Advanced endometrial carcinoma (EC) is typically associated with poor prognosis. However, recent advances have revolutionized therapeutic strategies. In patients with microsatellite stable (MSS) advanced EC, pembrolizumab plus lenvatinib have significantly improved overall survival, progression-free survival and response rate compared to standard chemotherapy. We describe the case of a 63-year-old woman with advanced endometrioid adenocarcinoma exhibiting mismatch repair proficiency (pMMR) and MSS who started treatment with pembrolizumab and lenvatinib after failing multiple lines of therapy. The patient had a favourable response, with mild side effects, and continues to receive treatment. Our experience supports pembrolizumab plus lenvatinib as a promising therapeutic option for patients with advanced recurrent EC with pMMR/MSS. This article is part of the New treatment options for advanced endometrial carcinoma Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.

查看原文本刊更多论文

派姆单抗-lenvatinib在重度预处理复发性子宫内膜癌患者中的持续疾病控制：1例报告。

晚期子宫内膜癌（EC）通常伴有不良预后。然而，最近的进展已经彻底改变了治疗策略。在微卫星稳定（MSS）晚期EC患者中，与标准化疗相比，派姆单抗加lenvatinib显著提高了总生存期、无进展生存期和反应率。我们描述了一例63岁晚期子宫内膜样腺癌女性，表现出错配修复能力（pMMR）和MSS，她在多次治疗失败后开始使用派姆单抗和lenvatinib治疗。患者有良好的反应，副作用轻微，并继续接受治疗。我们的经验支持派姆单抗联合lenvatinib作为晚期复发性EC伴pMMR/MSS患者的一种有希望的治疗选择。这篇文章是晚期子宫内膜癌新治疗方案的一部分特刊：https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.